WilliamJohnsonIrvinJr.MD

Oncology • Midlothian, VA

Assistant Professor, Medicine, University of North Carolina-Chapel Hill School of Medicine

Join to view full profile

Dr. Irvin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Irvin's full profile

Already have an account?

Office
14051 St Francis Blvd
Suite 2210
Midlothian, VA 23114
Phone+1 804-893-8717

Fax+1 804-594-3131

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2006 - 2009
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2003 - 2006
Virginia Commonwealth University School of MedicineClass of 2003

Certifications & Licensure

VA State Medical License 2003 - 2026
NC State Medical License 2006 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Start of enrollment: 2008 Jun 18
Completed
Phase 2
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.
Jonathan D Sorah, Allison M Deal, Sophia I Stein, Mattias Jonsson, Federico Innocenti
The Oncologist. 2024-09-06
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.
Hanna K Sanoff, Allison M Deal, Jai Patel, Jonathan D Sorah, Jacquelyne Gaddy
The Oncologist. 2024-09-06
8 citations
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial.
Wendy Y Chen, Karla V Ballman, Ann H Partridge, Olwen M Hahn, Frederick M Briccetti
JAMA. 2024-05-28

Press Mentions

Bon Secours Offering New Therapy to Help Reduce Hair Loss Caused by ChemoOctober 2nd, 2019
How the Sisters Network Plans to Save Women’s Lives This YearSeptember 27th, 2019
Medical Options for the Treatment of Breast Cancer on Coast LiveOctober 26th, 2018